- Conditions
- Hypertension
- Interventions
- Valsartan 0.25 mg/kg, Valsartan 1.0 mg/kg, Valsartan 4.0 mg/kg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- USA, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 18,300
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 10
- States / cities
- La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
- Conditions
- Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
- Interventions
- UX007, Placebo
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 1 Year to 100 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Miami, Florida • Orlando, Florida + 4 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
- Interventions
- OSI-906, erlotinib, placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Port Saint Lucie, Florida • Albany, Georgia + 4 more
- Conditions
- Pulmonary Arterial Hypertension, Children
- Interventions
- Sildenafil citrate, Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
- Conditions
- Generalized Anxiety Disorder
- Interventions
- JNJ-99245354, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Temecula, California • Miami, Florida • Springfield, Massachusetts + 1 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- EDP-305 1 mg, EDP-305 2.5 mg, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 40
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Coronado, California + 28 more
- Conditions
- Fibromyalgia
- Interventions
- Lu AG06466, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Major Depressive Disorder
- Interventions
- BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone), Matching placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 9
- States / cities
- Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Ortho-Cyclen, Dolutegravir, Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Osteoarthritis
- Interventions
- Ketoprofen Topical Patch , 20%
- Drug
- Lead sponsor
- Alkemira SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Healthy Adult Subjects
- Interventions
- ONO-2952, Placebo
- Drug
- Lead sponsor
- Ono Pharma USA Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Osteoarthritis of the Knee
- Interventions
- honeybee venom (Apitoxin (Korea) Apitox (USA))
- Drug
- Lead sponsor
- Apimeds, Inc.
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- Pinellas Park, Florida • Chicago, Illinois • Columbus, Ohio + 1 more
- Conditions
- Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
- Interventions
- Omadacycline Oral Tablet, Placebo
- Drug
- Lead sponsor
- Paratek Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 17
- States / cities
- Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more
- Conditions
- Nasal Congestion
- Interventions
- Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg
- Drug
- Lead sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 1,021 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 12
- States / cities
- Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more
- Conditions
- PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder
- Interventions
- COMP360 psilocybin
- Drug
- Lead sponsor
- COMPASS Pathways
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Irvine, California • Los Angeles, California + 14 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Apremilast 30 mg, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Palm Desert, California • Brandon, Florida + 20 more
- Conditions
- Gaucher Disease
- Interventions
- Plant cell expressed recombinant glucocerebrosidase (prGCD)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Coral Springs, Florida • Decatur, Georgia • New York, New York
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Telitacicept, Placebo
- Biological
- Lead sponsor
- Vor Biopharma
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Anniston, Alabama • Mission Hills, California • Orange, California + 9 more
- Conditions
- Epilepsy, Epilepsy, Generalized, Seizures
- Interventions
- Clobazam Low Dose, Clobazam Medium Dose, Clobazam High Dose, Placebo
- Drug
- Lead sponsor
- Lundbeck LLC
- Industry
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 34
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
- Interventions
- Camoteskimab, Placebo
- Drug
- Lead sponsor
- Apollo Therapeutics Ltd
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 26 more
- Conditions
- Osteoarthritis
- Interventions
- PH-797804, Placebo, Naproxen, Naproxen + PH-797804
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 26
- States / cities
- Paramount, California • Spring Valley, California • Valley Village, California + 20 more
- Conditions
- Allergic Rhinitis
- Interventions
- JNJ-17166864, Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hypertension
- Interventions
- Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 101
- States / cities
- Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more